Research

Recent Publications

  • Muñoz-Vergara, Dennis, Yan Ma, EunMee Yang, Sarah Jaehwa Park, Wren M Burton, Eunjung Kim, JoAnn E Manson, Gloria Y Yeh, Peter M Wayne, and Howard D Sesso. (2026) 2026. “Use of Complementary Health Approaches and Research Interests Among Older Adults in the COSMOS Trial.”. The American Journal of Medicine. https://doi.org/10.1016/j.amjmed.2026.04.001.

    OBJECTIVE: We examined the prevalence and patterns of complementary health approaches (CHA) use and interest in CHA research participation among COSMOS older adults.

    METHODS: We conducted cross-sectional analyses of the COSMOS Study 2024 survey that asked participants about their use of and research interest in six CHA categories (manual therapies, mind-body therapies, herbal products, acupuncture, spiritual practices, and cannabis/psychedelics). We compared key baseline sociodemographic, lifestyle, and clinical characteristics between CHA users and non-users overall, and for each CHA category. We used multivariable logistic regression models to estimate the odds of CHA use in the past 12 months and ever in lifetime.

    RESULTS: Of the 16,144 participants who responded (median age, 77.5 y), 58.8% and 76.4% indicated using CHA at least once in the past 12 months and ever in lifetime, respectively, and 50.4% reported interest in participating in CHA research. The highest prevalence of recent use was observed for spiritual practices (38.6%; 95% CI, 37.8- 39.3) and lifetime use for manual therapies (51.9%; 95% CI, 51.2-52.7). A history of falls or depression was linked to higher odds of recent and lifetime CHA use.

    CONCLUSIONS: The high prevalence of selected CHA highlights the need to identify evidence gaps for safety, harm, and public health impact for new focused research studies. Limited generalizability to more diverse and medically underserved populations underscores the need for continued integrative health research.

  • Plante, Timothy B, Yifei Sun, Pallavi P Balte, Donald Lloyd-Jones, Hongyan Ning, Norrina Allen, Morgana Mongraw-Chaffin, et al. (2026) 2026. “Life’s Essential 8 and Risk of Severe COVID-19 Among Adults Without Clinical Cardiovascular Disease: The C4R Study.”. Journal of the American Heart Association, e048256. https://doi.org/10.1161/JAHA.125.048256.

    BACKGROUND: Cardiovascular disease is a risk factor for severe COVID-19 (ie, hospitalization or death). Whether better cardiovascular health (CVH) is associated with lower risk of severe COVID-19 among adults without cardiovascular disease is unknown. We aimed to test if the American Heart Association's Life's Essential 8 (LE8) metric and its components were associated with severe COVID-19 in the C4R (Collaborative Cohort of Cohorts for COVID-19 Research) consortium.

    METHODS: Participants with cardiovascular disease were excluded. Two waves of questionnaires, events surveillance, and a serosurvey identified COVID-19 infections. Associations of incident severe COVID-19 with continuous LE8, categorical LE8 (low [<50], moderate [50 to <80], and high [≥80] CVH), and individual LE8 components, were tested in adjusted cause-specific hazards models.

    RESULTS: Among 29 740 participants in 9 cohorts (mean age, 66±14 years; 61% women; 35% White race; 22% Black race; 34% Hispanic ethnicity), there were 681 severe COVID-19 cases between March 1, 2020, and February 28, 2023. There was a 20% lower hazard of severe COVID-19 per each 1-SD higher LE8 (adjusted hazard ratio [aHR], 0.80 [95% CI, 0.73-0.88]). Relative to low CVH, high CVH was associated with lower risk of severe COVID-19 (aHR, 0.54 [95% CI, 0.37-0.78]); this was not seen for moderate CVH (aHR, 0.81 [95% CI, 0.64-1.04]). Of LE8 components, better physical activity, body mass index, blood pressure, and sleep were associated with a lower hazard of severe COVID-19.

    CONCLUSIONS: Better CVH was associated with lower severe COVID-19 risk among cardiovascular disease-free adults. Whether CVH optimization could mitigate adverse risk from COVID-19 and other harmful viruses warrants further investigation.

  • Koster, Kyle M, Francesca Minardi, Abigail Feinberg, Mara Schonberg, Julie B Schnur, Juan P Wisnivesky, Michael A Diefenbach, and Minal S Kale. (2026) 2026. “Pretest-Posttest Trial of a Lung Cancer Screening Decision Aid for Individuals With Multimorbidity from a Primary Care Population.”. PEC Innovation 8: 100473. https://doi.org/10.1016/j.pecinn.2026.100473.

    OBJECTIVE: This study pilot tested a novel Decision Aid (DA) that clarifies the impact of multimorbidity on Lung Cancer Screening (LCS) risks and benefits. Outcomes of interest include LCS knowledge, disposition to complete LCS, decisional conflict and confidence.

    METHODS: Evaluation scales were administered before and after DA exposure to 50 patients with smoking history; 70% of them having moderate or severe multimorbidity.

    RESULTS: LCS Knowledge Measure scores improved (median 3 vs. 5 on scale 0-12, p < 0.0001). Scores of Decisional Conflict subscale related to feeling uninformed improved (median 3.5 vs. 3 on scale 0-15, p = 0.03). Overall Decisional Conflict (median 16 vs. 16 on scale 0-80), Stage of Decision Making (median 4 vs. 4 on scale 1-4), and share of participants disposed to complete LCS (86% vs. 84%) were similar.

    CONCLUSION: Exposure to a DA tailored to individuals with multimorbidity was associated with improved knowledge of LCS. Further investigation is needed to evaluate the DA efficacy in patients with higher baseline decisional conflict and lower baseline confidence.

    INNOVATION: A novel DA presenting information on the impact of comorbidities on LCS risks and benefits was found to hold potential for better supporting the decision-making of patients with multimorbidity.

  • Hussain, Zaib, Timothy B Plante, Azuka Amaka Ngige, Hailey N Miller, Joyline Chepkorir, Stephen P Juraschek, Seth S Martin, Allison G Hays, and Erin D Michos. (2026) 2026. “Knowledge of Clinical Trials by Disease Status: A Health Information National Trends Survey (HINTS) Study.”. Contemporary Clinical Trials 165: 108319. https://doi.org/10.1016/j.cct.2026.108319.

    BACKGROUND: While clinical trials (CTs) are crucial for advancing healthcare, public knowledge remains limited. Individuals with cancer may be more engaged with experimental treatments than those with other chronic conditions like cardiovascular disease (CVD). Whether CVD patients have comparable CT knowledge, and how this varies by sociodemographic factors, remains unclear.

    OBJECTIVES: To examine CT knowledge variation between individuals with cancer and CVD and identify sociodemographic correlates of knowledge within CVD population.

    METHODS: HINTS is a nationally representative survey of U.S. adults aged ≥18 years. Participants self-reported cancer history, CVD status, and CT knowledge. Logistic regression assessed associations between disease status and CT knowledge, adjusting for sociodemographic and health factors. Within CVD group, variables with P < 0.25 in univariable models were retained in multivariable model. Analyses applied sampling weights.

    RESULTS: Among a weighted sample (n = 3772) representing ∼250 million (mean [SD] age, 57 [17.0] years; 50% women), 6% reported cancer and 8% CVD. CT knowledge was 61% in CVD and cancer groups; 35% of CVD group were low-income. In adjusted models, CT knowledge among cancer-only (OR 1.09, 95%CI 0.70-1.68) and CVD-only (OR 1.26, 95%CI 0.73-2.18) groups did not differ significantly from adults without CVD or cancer. Among CVD population, lower income participants (OR 0.24, 95%CI 0.06-0.98) had significantly lower odds of CT knowledge.

    CONCLUSION: Most adults with CVD and cancer lacked CT knowledge, underscoring need for broader education. Reduced income was independently associated with diminished knowledge, suggesting targeted efforts may benefit underserved patients and expand access to innovative therapies.